We retrospectively enrolled 194 NSCLC patients harboring EGFR mutations who received EGFR-TKIs.Clinical characteristics were collected, and the relation between the efficacy of EGFR-TKIs and pretreatment serum CYFRA21-1 and CEA was analyzed. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.